From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites ...
With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, ...
Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered ...
Red-hot generative AI specialist Insilico Medicine has teamed up with another major biopharma player, this time linking up ...
As Pfizer and Moderna have tied off certain threads in their separate webs of mRNA patent litigation, Sanofi has opened a new ...
In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish ...
With a midstage peek at the data on Veradermics’ oral formulation of the molecule behind the ubiquitous hair regrowth treatment Rogaine, analysts are feeling increasingly confident that the New Haven, ...
In an initiative to increase the efficiency of drug manufacturing in the United States, the FDA has proposed a streamlined ...
Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for ...
A bipartisan bill reintroduced by three senators aims to increase transparency around foreign influence on the United States’ ...
Kelun scores sac-TMT win in first-line NSCLC population missing from Merck’s massive phase 3 program
The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), could add a missing piece thanks to a landmark achieved by its partner ...
Huyabio has scored a win in the largest oncology study it has undertaken in its 22 years, as its oral histone deacetylase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results